SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

osavampator

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3
Time to market
If Phase 3 succeeds, an NDA submission would likely follow in late 2027 or 2028, with potential FDA approval in 2028-2029, assuming standard review timelines.
Why 6/10
The next hard, dated catalyst is the Phase 3 pivotal topline readout for osavampator in MDD, expected in H2 2027 (estimated primary completion July 2027 per ClinicalTrials.gov). This is roughly 8-14 months from today, placing it within the ~6-12 month window. Osavampator is a major pipeline value driver, but Neurocrine is a diversified company with the approved blockbuster INGREZZA generating over $1B in quarterly revenue and another Phase 3 program (direclidine in schizophrenia) also reading out in 2027, so the binary risk is contained.
Actionable Insight NEUTRAL

The next major catalyst is the Phase 3 topline readout for osavampator in MDD, expected in the second half of 2027. Positive data would validate a novel AMPA-receptor mechanism in depression and open a large adjunctive-MDD market opportunity. Negative data would remove a key pipeline growth driver but would not threaten Neurocrine's existing INGREZZA franchise. Watch for interim updates or trial-completion announcements from ClinicalTrials.gov (NCT06786624, estimated primary completion July 2027).

Price Chart

Loading chart...

Executive Summary

Osavampator (TAK-653 / NBI-1065845) is Neurocrine Biosciences' Phase 3 AMPA receptor positive allosteric modulator for major depressive disorder as an adjunctive therapy. Phase 2 SAVITRI data showed statistically significant MADRS score reductions and good tolerability, leading to a five-study Phase 3 registrational program launched in January 2025. The pivotal readout is expected in the second half of 2027, roughly 8-14 months from now. Osavampator is a meaningful pipeline asset for Neurocrine, but the company is diversified with the already-approved blockbuster INGREZZA (valbenazine) generating over $1B in quarterly revenue, reducing the binary risk.

How It Works

Osavampator is a positive allosteric modulator (PAM) of the AMPA receptor, a protein on brain cells that responds to the neurotransmitter glutamate. Rather than directly activating the receptor, it amplifies the brain's natural glutamate signal by slowing how fast the receptor turns off. This is thought to enhance mood-regulating circuits in the brain. It is taken as a once-daily oral pill.

Trial Status

Neurocrine initiated a five-study Phase 3 registrational program in January 2025 following positive Phase 2 SAVITRI results. The key registrational trial (NCT06786624) is actively recruiting approximately 200 participants with an estimated primary completion date of July 2027. The Phase 2 SAVITRI study met its primary endpoint with a statistically significant 4.3-point placebo-adjusted reduction on the MADRS depression scale at Day 28, deepening to 7.5 points at around two months, with nearly half of patients reaching remission. The drug was well-tolerated with headache as the most common adverse event and no serious adverse events reported.

The Two-Sided Case

▲ Bull Case4
Phase 2 SAVITRI data showed statistically significant and clinically meaningful MADRS score reductions (4.3-point at Day 28, 7.5-point at ~2 months) with a favorable safety profile, supporting the mechanism's promise in treatment-resistant depression.
Osavampator is the most advanced AMPA receptor PAM in development for depression, targeting a large $15.8B addressable MDD market with significant unmet need for adjunctive therapies.
Neurocrine has a strong commercial track record with INGREZZA (>$1B quarterly revenue), providing ample funding for the Phase 3 program without dilution risk.
Analyst consensus is Strong Buy (32 buy/strong buy vs 5 hold, 0 sell) with a mean price target of $206, implying ~42% upside from the current ~$145 share price.
▼ Bear Case4
Phase 3 trials in depression have high failure rates; positive Phase 2 data does not guarantee Phase 3 success, especially given the modest effect size (4.3-point MADRS separation at Day 28).
The pivotal readout is not expected until H2 2027, leaving a long wait with no near-term binary catalysts for this drug specifically.
Competing mechanisms for treatment-resistant depression include NMDA antagonists (e.g., ketamine, already approved as Spravato), which could limit osavampator's commercial opportunity even if approved.
Insider selling (CFO, Chief Corp Affairs Officer via 10b5-1 plans) and several large institutional near-exits (Wellington, Millennium, D.E. Shaw) in Q2 2026 suggest some sophisticated investors are reducing exposure ahead of the 2027 readouts.

Upcoming Catalysts

  • Phase 3 topline data readout for osavampator in major depressive disorder, expected in the second half of 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 prnewswire.com3 prnewswire.com4 clinicaltrials.gov5 prnewswire.com6 stockanalysis.com7 biospace.com8 synapse.patsnap.com9 assetmemo.bio10 psychiatrictimes.com